X4 Pharmaceuticals, INC Form 4 insider transactions

X4 Pharmaceuticals' Chief Commercial Officer, Mark Baldry, sold 29,159 shares after the vesting of performance-based restricted stock units.

X4 Pharmaceuticals' Chief Operating Officer, Mary DiBiase, sold 22,258 shares after the vesting of 61,178 performance-based restricted stock units.

X4 Pharmaceuticals' Chief Medical Officer, Christophe Arbet-Engels, sold 11,624 shares after the vesting of performance-based restricted stock units.

X4 Pharmaceuticals' CEO, Paula Ragan, sold 31,897 shares of common stock at a weighted average price of $0.3945 per share, as part of a pre-arranged 10b5-1 trading plan.

Paula Ragan, CEO of X4 Pharmaceuticals, sold 31,897 shares of common stock at an average price of $0.562 per share on October 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Chief Financial Officer Adam S. Mostafa of X4 Pharmaceuticals reports acquisition and disposal of common stock, including shares earned from vested performance-based restricted stock units and sales under a 10b5-1 trading plan.

Mark Baldry, Chief Commercial Officer of X4 Pharmaceuticals, reports acquisition and disposal of company stock.

Paula Ragan, CEO of X4 Pharmaceuticals, reports the acquisition and disposal of company stock, including shares earned from vested performance-based restricted stock units and sales under a 10b5-1 trading plan.

Mary DiBiase, COO of X4 Pharmaceuticals, reports the acquisition and disposal of company stock, including shares earned from vested performance-based restricted stock units and sales under a 10b5-1 trading plan.

Arthur Taveras, Chief Scientific Officer of X4 Pharmaceuticals, reports acquisition of shares through vesting of performance-based restricted stock units and subsequent sale of shares under a 10b5-1 trading plan.

Mary DiBiase, COO of X4 Pharmaceuticals, sold 2,642 shares of common stock on September 9, 2024, to cover personal income tax obligations related to a restricted stock unit award.

Director de Craecker Francoise of X4 Pharmaceuticals, Inc. was granted 45,000 restricted stock units (RSUs) as an annual award for board service.

Director William Aliski of X4 Pharmaceuticals reports acquiring 45,000 shares and disposing of shares in a recent transaction involving restricted stock units.

David W J McGirr, a director of X4 Pharmaceuticals, Inc., was granted 45,000 restricted stock units as an annual award for board service.

Director Stewart Murray reported acquiring 45,000 shares of X4 Pharmaceuticals, Inc. as restricted stock units.

Director Gary Bridger acquired 45,000 shares of X4 Pharmaceuticals as part of an annual award for board service.

Director Keith Woods reports the acquisition of 45,000 shares of common stock and disposal of 135,000 shares of common stock in X4 Pharmaceuticals, Inc.

Alison Frances Lawton, a director at X4 Pharmaceuticals, acquired 45,000 shares of common stock on June 10, 2024, as part of a restricted stock unit (RSU) grant.

Michael S. Wyzga, a director at X4 Pharmaceuticals, acquired 45,000 shares of common stock through a restricted stock unit (RSU) grant.

Arthur Taveras, Chief Scientific Officer of X4 Pharmaceuticals, sold 14,235 shares of common stock on March 11, 2024, to cover personal income tax obligations related to a restricted stock unit award.

Paula Ragan, CEO of X4 Pharmaceuticals, sold 49,678 shares of common stock on March 11, 2024, to cover personal income tax obligations related to the settlement of a restricted stock unit award.

Adam S. Mostafa, CFO of X4 Pharmaceuticals, sold 52,500 shares of common stock at a weighted average price of $0.8828 on March 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Mary DiBiase, COO of X4 Pharmaceuticals, sold 15,409 shares of common stock on March 11, 2024, to cover personal income tax obligations related to the settlement of a restricted stock unit award.

Christophe Arbet-Engels, Chief Medical Officer of X4 Pharmaceuticals, files an amendment to a Form 4 to correct the number of stock appreciation rights (SARs) awarded on February 13, 2024.